Stock Photo - 07 April 2022, Argentina, Garin: View of the mAbxience pharmaceutical company logo at the entrance to its facility. The facility produces 3 million doses of AstraZeneca's Corona drug and 100 kilograms of monoclonal antibodies annually. The company specializes in cancer and immune diseases. In 2022, Fresenius announced the purchase of a 55 percent stake in mAbxience. Photo: Florencia Martin/dpa. - Garin/Buenos Aires/Argentina

Stock Photo: 07 April 2022, Argentina, Garin: View of the mAbxience pharmaceutical company logo at the entrance to its facility. The facility produces 3 million doses of.

Searchable keywords

Choose multiple keywords